(Reuters) – AstraZeneca said on Monday it would pay up to $1.9 billion to CSPC Pharmaceutical Group Ltd in an exclusive license agreement to boost the Anglo-Swedish drugmaker’s cardiovascular pipeline.
CSPC will get an upfront payment of $100 million to develop an early-stage, novel small molecule Lipoprotein (a) disruptor that could offer benefits to patients with dyslipidaemia, a disease characterised by elevated levels of so-called bad cholesterol, AstraZeneca said.
(Reporting by Yadarisa Shabong in Bengaluru)
